NewswireToday - /newswire/ -
London, United Kingdom, 2007/11/28 - Report Buyer, the online destination for business intelligence, has added a new report showing that growth in the use of cardiovascular drugs has been steady in the last five years at around three percent compound annual growth rate (CAGR) and growth.
“Commercial Insight: Cardiovascular market overview” reports that despite growth in the use of cardiovascular drugs, sales growth is unlikely to match this. Growth in the last five years has been moderate at eight percent CAGR but there is likely to be negligible growth between now and 2016, giving an effective fall of three percent in cardiovascular revenues.
The report shows that sales growth is being hindered by the loss of patent protection on key cardiovascular blockbusters and the uptake of generic versions of leading drugs, as cost containment measures are promoted by national healthcare providers. Some of the brands losing patent protection during the 2010 to 2013 window include Pfizer’s Lipitor, the world’s number one selling brand, Sanofi Aventis/Bristol-Myers Squibb (BMS) Plavix, the best selling platelet aggregation inhibitor, and the anti-hypertensive, Novartis’ Diovan.
Authors of the report say the uptake of generic versions of these drugs is expected to be heavily promoted in an effort to reduce healthcare budgets and branded sales will slump accordingly. They note that replacement drugs currently in development are unlikely to be able to fill the void left by the loss of these blockbusters.
The report shows that many cardiovascular diseases now have an array of generic drugs that provide effective treatment without the need to resort to expensive branded products. This provides a major challenge to pharmaceutical companies as any new drug must be able to demonstrate significant clinical benefit to meet the cost effectiveness criteria determined by healthcare providers. According to the report, as a consequence, future blockbusters will not be of the same scale as the current crop. Byetta LAR is likely to be the best performing of the drugs currently in development and is predicted to have peak sales of $3 billion in the seven major markets. This compares to the sales of Lipitor in 2006 of $11.2 billion
However, the study shows that the one disease area which will continue to grow in the cardiovascular franchise is diabetes. With the majority of the western world in the grips of an obesity epidemic, the number of sufferers of type 2 diabetes will continue to increase at a rapid clip. Pharmaceutical companies have invested heavily in this area to meet unmet clinical needs and a large proportion of the top 10 cardiovascular brands in 2016 will be diabetes therapies.
The complex nature of insulin formulations and the lack of generic competition from biosimilar versions have safeguarded sales and margins of insulin products after the loss of patent protection. Biosimilar legislation which will provide marketing authorization for biosimilars is currently held up in both the US Congress and Senate as vested interests delay the approval of the bills.
The ‘patent cliff’ will be most acutely felt by Pfizer as patent protection in the US for Norvasc was lost in 2007 and Lipitor will be lost in 2010. Adding insult to injury, Pfizer’s current cardiovascular pipeline is particularly bare after the company dropped the development of the Lipitor replacement, torcetrapib, and the withdrawal of Exubera, an inhaled insulin which some analysts had predicted would generate $2 billion in annual sales but only generated $5 million in the US in the first half of 2007.
The report predicts revenue losses for many drug makers in the cardiovascular market once the ‘patent cliff’ takes effect. However, Pfizer will be acutely affected, with a net loss in cardiovascular revenue of $12 billion, with Sanofi-Aventis becoming the largest player in the cardiovascular market by 2009.
“Commercial Insight: Cardiovascular market overview” is available from Report Buyer. For more information visit the website.
Report Buyer product ID: DAT08267
About Report Buyer
Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare. The website now carries over 40,000 business information products, including market reports, studies and books. Report Buyer is the intelligent way to buy market research making it an essential resource for executives and information buyers worldwide. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.